China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
May 10, 2022 at 09:01 am EDT
Share
China Health Industries Holdings, Inc. reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported sales was USD 0.000001 million compared to USD 0.778675 million a year ago. Net loss was USD 0.278922 million compared to net income of USD 0.102032 million a year ago. Basic loss per share from continuing operations was USD 0.0043 compared to basic earnings per share from continuing operations of USD 0.0016 a year ago.
For the nine months, sales was USD 0.000269 million compared to USD 6.06 million a year ago. Net loss was USD 0.873833 million compared to net income of USD 1.56 million a year ago. Basic loss per share from continuing operations was USD 0.0133 compared to basic earnings per share from continuing operations of USD 0.0238 a year ago.
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.
CHINA HEALTH INDUSTRIES HOLDINGS, INC. 